NCT06273774View on ClinicalTrials.gov

A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

August 21, 2024

Study Completion Date

August 21, 2024

Conditions
Bipolar I Disorder
Interventions
DRUG

MK-8189

Oral Tablet

DRUG

Placebo

Oral Tablet

Trial Locations (3)

30331

Atlanta Center for Medical Research ( Site 0001), Atlanta

72211

Woodland International Research Group-Clinical Research ( Site 0009), Little Rock

08053

Hassman Research Institute Marlton Site ( Site 0006), Marlton

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06273774 - A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020) | Biotech Hunter | Biotech Hunter